Project/Area Number |
26861474
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
Ophthalmology
|
Research Institution | Osaka Medical College |
Principal Investigator |
|
Project Period (FY) |
2014-04-01 – 2016-03-31
|
Project Status |
Completed (Fiscal Year 2015)
|
Budget Amount *help |
¥3,250,000 (Direct Cost: ¥2,500,000、Indirect Cost: ¥750,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
Keywords | 糖尿病網膜症 / 局所投与 / PLGA / アンジオテンシン / 血管透過性 / VEGF / ICAM-1 / MCP-1 |
Outline of Final Research Achievements |
The purpose of this research was to determine whether periocular candesartan, an angiotensinII typeI receptor antagonist, -poly(lactic-co-glycolic acid : PLGA) microparticles alleviate diabetes-induced inflammation in Sprague Dawley rats. Treatment with periocularly administered candesartan-PLGA microparticles significantly decreased the permeability of the retinal microvessels. The number of adherent leukocytes was significantly reduced, together with retinal VEGF, ICAM-1 and MCP-1 in the diabetic+candesatan group compared with the diabetic group. The periocular administration of candesartan-PLGA microparticles inhibit diabetes-induced retinal inflammatory damage, indicating their potential usefulness in treating diabetic retinopathy.
|